Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) reported first quarter 2026 revenue of $5.6 million, up 6.7% sequentially but below $6.8 million a year earlier, mainly due to non-recurring prior pharma revenue. GAAP gross margin was 57%; operating expenses fell to $10.5 million (down 21% YoY), cutting operating loss to $7.3 million. Net loss was $8.2 million. Cash and short-term deposits totaled $20 million, with $6 million net cash used in operations. Channel partnerships provide access to over 116 million covered lives, with a new contract in progress that could raise reach above 175 million. DarioHealth added 10 new accounts and reported a $127 million pipeline across 241 active opportunities.
DarioHealth (Nasdaq: DRIO) will report first quarter 2026 financial results for the period ended March 31, 2026 and will host a live conference call and webcast on Wednesday, May 13, 2026 at 8:30 a.m. ET, before the market opens.
Executives Erez Raphael, Steven Nelson, and Chen Franco-Yehuda will host. A replay will be available through Wednesday, May 27, 2026.
DarioHealth (NASDAQ: DRIO) announced a peer‑reviewed JMIR Formative Research publication (April 20, 2026) reporting statistically significant improvements in workplace functioning from its digital behavioral health program.
Among users, focus and task completion improved within six weeks (n=1,254 for concentration), with larger gains by weeks 6–10; comparable gains seen for procrastination (n=1,004) and mistakes at work (n=167).
DarioHealth (NASDAQ: DRIO) appointed veteran healthcare executive John R. Palumbo to its Board of Directors effective April 13, 2026. Palumbo brings more than 40 years of healthcare operating experience, board service, and relationships across payers, health systems and provider services to support accelerated commercial scaling.
The appointment aligns board composition with a partner-led, capital-efficient go-to-market strategy and aims to expand channel partnerships and commercial momentum.
DarioHealth (NASDAQ: DRIO) reported Q4 2025 revenue of $5.2M and full-year 2025 revenue of $22.4M versus $27.0M in 2024, driven by a legacy client nonrenewal after the Twill acquisition.
Key metrics: GAAP gross margin 57%, pipeline $122M, contracted/late-stage ARR $12.9M, cash $26M, and full-year operating expenses down 31% to $49.3M.
DarioHealth (Nasdaq: DRIO) will report fourth quarter and full year 2025 results before the market opens on Thursday, March 19, 2026.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda. A replay will be available through Thursday, April 2, 2026.
DarioHealth (NASDAQ: DRIO) published a peer-reviewed ML study in Frontiers in Digital Health on March 10, 2026, analyzing real-world data from 22,414 adults with type 2 diabetes.
Researchers used generalized linear mixed-effects tree models and found sustained blood glucose improvements linked to higher digital engagement; 12 measurements per month emerged as an actionable threshold for glycemic improvement.
DarioHealth (NASDAQ: DRIO) positions its digital platform to boost real-world outcomes for patients using oral GLP-1 therapies by embedding precision behavioral support at scale. Key facts: 79% of members use Dario's weight management, and oral GLP-1s are projected to capture 25% of the GLP-1 market worth $95B by 2030 per Goldman Sachs. Dario highlights medication adherence tools, a grocery scanner and human coaches to reduce dose-timing drift, manage side effects and improve persistence for payers and employers.
DarioHealth (NASDAQ: DRIO) announced it has surpassed 100 peer-reviewed studies and conference abstracts as of Jan 21, 2026, reinforcing its evidence base for employers, health plans and members.
The research portfolio includes large study populations, longitudinal designs (some up to two years), independent third-party investigator-initiated studies, and directly observed outcomes such as actual claims reduction and measured HbA1c improvement. Dario says the body of work positions it among the most evidence-based digital health vendors and supports value-based purchasing and vendor consolidation decisions.
Dario Health (NASDAQ: DRIO) launched DarioIQ™, a new conversational AI layer in the Dario Health app, rolling out a direct-to-consumer first version on Dec 10, 2025 to an opt-in cohort of hypertension members.
DarioIQ™ integrates behavioral insights, real-time biometric interpretation, device connectivity and human coaching across three components — Advisor, Sentinel and Strategist — and builds on the company’s proprietary AI models and 13 billion real-world data points. The company plans staged expansion to employers and health plans and to other chronic pathways including diabetes and weight management, prioritizing safety and clinical validation.